“The aim of this study … to verify whether combinations of lapatinib with one of isothiocyanates ( sulforaphane , erucin or sulforaphene), targeting different levels of HER2 signaling pathway, exert stronger cytotoxic effect than therapy targeting the receptor only, using heterogeneous populations consisting of lapatinib-sensitive and lapatinib-resistant breast cancer cells.”